Study met primary end point and demonstrated successful subcutaneous administration of a 10 mL biologic co-formulated with ENHANZE® in 30 seconds using Halozyme's proprietary high-volume auto-injector ...
AstraZeneca’s SAPHNELO ® (anifrolumab-fnia) has been approved in the US for self-administration as a once-weekly autoinjector ...
An on-body delivery system approved last fall for paroxysmal nocturnal hemoglobinuria (PNH) has seen rapid uptake and is now being studied for use with isatuximab. Improving cancer care isn’t just ...
TOKYO and CAMBRIDGE, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (BIIB) (Nasdaq ...
WALTHAM, Mass., June 26, 2017 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that the U.S. Food and Drug Administration (FDA) accepted the supplemental new drug ...
Please provide your email address to receive an email when new articles are posted on . The FDA has accepted Eisai and Biogen’s biologics license application for a subcutaneous autoinjector weekly ...
Study met primary end point and demonstrated successful subcutaneous administration of a 10 mL biologic co-formulated with ENHANZE® in 30 seconds using Halozyme's proprietary high-volume auto-injector ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results